Company news

Johnson & Johnson (NYSE:JNJ) news

Johnson & Johnson news releases on 6ix. Latest, Oct 2, 2026: Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque…

Johnson & Johnson (NYSE:JNJ) news

Press releases & updates

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion

Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

New model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

Johnson & Johnson : New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses

Johnson & Johnson : presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

New clinical evidence presented at PAINWeek 2026 demonstrates the powerful, long-lasting relief of TYLENOL® with Naproxen in post-surgical pain studies

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

Johnson & Johnson : Announces New Global Classification System for Surgical Outcomes

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care

Johnson & Johnson : Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence

Johnson & Johnson Announces MONARCH QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

Johnson & Johnson : Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Johnson & Johnson : Second Quarter 2026 2026 Second-Quarter Earnings Transcript

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Johnson & Johnson : Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson - DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer

Johnson & Johnson : DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform